Founded in 2002, Aptus Endosystems has developed an endograft and endovascular stapling system delivered via standard catheter technology.
According to Aptus Endosystems, the helical staple technology enables independent endograft fixation and is designed to approximate suturing in an open surgical anastomosis. The company continues to build on its US clinical experience which includes 176 patients and deployment of more than 900 EndoStaples.
Jeff Elkins, CEO of Aptus Endosystems, said: “Completing our first cases in Europe marks a significant milestone for Aptus Endosystems. This initial commercial experience supports the success that we saw with our EndoStapling System in the US. The novel concept of independent and physician controlled proximal fixation using the EndoStapling System is a considerable step toward preventing long term complications and making EVAR the definitive solution in treating aortic aneurysms.”
Of the procedures performed to date in Europe, the Aptus EndoStapling System was used for secondary interventions to repair previously implanted endografts as well as in de novo aortic aneurysm patients, where the surgeon(s) believed that long term patient outcomes would be improved with the addition of radial fixation of the endograft with the EndoStaple.
The Aptus Endovascular AAA Repair Systems bear the CE marking for distribution in the European Union. The products are investigational use only in the US.
